A selective β1-adrenergic receptor blocker with no membrane stabilizing effect and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility.

It can relax the sphincter of Oddi, has strong antispasmodic and analgesic effects, and can also gently and continuously promote bile secretion, strengthen gallbladder contraction and antibacterial effects, has obvious choleretic effects, is conducive to the discharge of stones, and has a certain stone discharge effect on common bile duct stones. Some patients with elevated alanine aminotransferase will return to normal after taking the medicine as the inflammation is eliminated. This product has low toxicity, and the acute toxicity LD50 of mice is 5375mg/kg.

Not yet clear

Not yet clear

Not yet clear

Not yet clear

The results of the genetic toxicity test were negative; no teratogenic effects were found in rats taking glibenclamide at a dose of 300 mg/kg/day; rats were given glibenclamide for 18 consecutive months at a dose of 300 mg/kg/day, and no carcinogenicity was observed; mice were given glibenclamide for 2 consecutive years and no carcinogenicity was observed.

The results of the genetic toxicity test were negative; no teratogenic effects were found in rats taking metformin 600 mg/kg/day; the results of studies on lactating rats showed that metformin hydrochloride can be secreted into breast milk and can reach plasma levels.